Introduction
============

The gastrointestinal stromal tumors (GISTs) represent less than 1% of all malignancies, but they are the most common mesenchymal neoplasms of the gastrointestinal tract.[@b1-cmo-6-2012-189]--[@b11-cmo-6-2012-189]

GIST arises from the wall of the gastrointestinal (GI) tract and is thought to originate from the Interstitial Cells of Cajal (ICC), which regulate the motility of the gastrointestinal tract.[@b10-cmo-6-2012-189],[@b19-cmo-6-2012-189]--[@b23-cmo-6-2012-189]

The most specific and important immunohistochemical marker is the KIT (CD117) protein, a tyrosine kinase growth factor receptor expressed in more than 95% of cases.[@b4-cmo-6-2012-189],[@b7-cmo-6-2012-189],[@b10-cmo-6-2012-189],[@b16-cmo-6-2012-189],[@b23-cmo-6-2012-189],[@b24-cmo-6-2012-189]

The gastrointestinal tract is the site of onset of elective GIST: 40%--70% originates from the stomach, 20%--40% from small intestine, 5%--15% from the colon and rectum and 5% from the esophagus.[@b10-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b25-cmo-6-2012-189],[@b26-cmo-6-2012-189]

More rarely neoplasms with histology and immunohistochemistry similar to GISTs may occur outside the gastrointestinal tract (omentum, mesentery and retroperitoneum) and are so-called Extra-gastrointestinal Stromal Tumors (EGISTs).[@b4-cmo-6-2012-189],[@b10-cmo-6-2012-189],[@b12-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b25-cmo-6-2012-189]--[@b32-cmo-6-2012-189],[@b58-cmo-6-2012-189]

Pathogenesis, incidence, clinicopathological features and prognosis of EGISTs have not been completely defined yet.[@b4-cmo-6-2012-189],[@b13-cmo-6-2012-189]--[@b15-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189]--[@b32-cmo-6-2012-189],[@b58-cmo-6-2012-189]

EGISTs arising in the retroperitoneum are extremely rare: to date there have been only 58 cases described in the literature.[@b4-cmo-6-2012-189],[@b12-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189]--[@b29-cmo-6-2012-189],[@b33-cmo-6-2012-189]--[@b35-cmo-6-2012-189],[@b58-cmo-6-2012-189] These tumors are of general interest both in diagnosis and treatment.

Since the preoperative diagnosis based on clinical and radiological data is very difficult[@b7-cmo-6-2012-189],[@b12-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b27-cmo-6-2012-189],[@b49-cmo-6-2012-189]--[@b51-cmo-6-2012-189] the patient undergoes a surgical operation for the generic diagnosis of "abdominal mass" which causes anxiety in both the surgeon and patient.

Surgical removal is the gold standard treatment for non-metastatic EGISTs and it is important to achieve a complete removal of the mass when possible "en bloc" with the contiguous tissues.[@b7-cmo-6-2012-189],[@b11-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b48-cmo-6-2012-189],[@b53-cmo-6-2012-189]--[@b55-cmo-6-2012-189]

The role of imatinib mesylate, which is the inhibitor of the tyrosine kinase activity of KIT in the treatment of EGISTs, is unclear.[@b11-cmo-6-2012-189],[@b13-cmo-6-2012-189],[@b57-cmo-6-2012-189],[@b59-cmo-6-2012-189]

As a result of the rarity of reports of primary EGISTs of retroperitoneum it is necessary to analyze the data of reported cases in order to define clearly the phenotypic and genetic characteristics as well as the prognostic factors and the optimal treatment of these rare tumors.

We herein report a case of a primary EGIST of the retroperitoneum surgically treated and discuss its clinical behavior and treatment through a literature review.

Case Report
===========

A 39-year-old man was admitted to our institute for abdominal back pain present for 4 months, without any other sign or symptom. The pain over time has gradually increased in intensity and was treated without benefit with analgesic drugs. Before admission, he underwent outpatient ultrasonography and abdominal computed tomography (CT) scan that showed a retroperitoneal solid mass (60 × 60 × 80 mm), placed in left paravertebral region, level L3--L4, on the left side of aorta, ilio-psoas muscle adherent. No adenopathies or local infiltrations were found. The bowel was dislocated without signs of intestinal occlusion ([Fig. 1](#f1-cmo-6-2012-189){ref-type="fig"}). The patient underwent CT-guided fine needle aspiration (FNA) with the result of inadequate sampling of the mass lesion. As part of clinical and instrumental workup he underwent standard blood tests, electrocardiogram (ECG) and chest X-ray, the results of which were normal. The patient's abdomen was normal and no mass was palpable. In view of patient's characteristics (a previous laparotomy for peritonitis due to acute appendicitis) and the dimension of the mass, an open procedure was preferred instead of laparoscopy approach. The laparotomy confirmed the presence of a solid and well defined mass located in the left paramedian region of the retroperitoneum. After sectioning the parietal peritoneum in the transition from the left colon and sigmoid colon, the mass was gradually exposed and removed. The tumor was completely excised (R0 resection). No perioperative complications were recorded and the patient was discharged four day after surgery. Postoperative pathologic evaluation revealed a 139---gram plurinodular mass, encapsulated, measuring 7.5 × 6 × 5.3 cm. After cutting, the tissue appeared brownish---yellow in color and had elastic consistency. Microscopically the tumor border was delineated from surrounding fat and no tumor cells were observed in the surgical margin. Microscopic examination also showed neoplastic proliferation composed by spindle cells type. Mitotic count was \<5 per 50 high-power fields (HPF) (low mitotic activity). The MIB-1 labelling index (monoclonal antibody used to determine the Ki-67 labelling index that is correlated with the clinical course of tumor) was 3%--5%. Immunohistochemistry showed positivity for KIT (CD 117) ([Fig. 2](#f2-cmo-6-2012-189){ref-type="fig"}), focal positivity for S-100 protein and NSE (neuron specific enolase), negativity for CD34, smooth and skeletal muscle actine. A molecular genetic analysis for KIT protein mutation was not performed due to its unavailability at our hospital. Morphological and immunohistochemical features leaded to a diagnosis of gastrointestinal stromal tumor which dimension and number of mitosis indicated an intermediate risk form according to risk assessment proposed by Fletcher et al[@b16-cmo-6-2012-189] and a low risk form according to the risk assessment proposed by Yamamoto et al.[@b4-cmo-6-2012-189] The further oncological evaluation did not consider necessary an adjuvant therapy with imatinib mesylate because the tumor was completely excised (resection R0) and it was classified as an intermediated-low risk form. An abdominal CT scan did not show any recurrence of disease in the 2 years after surgery.

Discussion
==========

The GISTs are the most common mesenchymal tumors of the gastrointestinal tract with an incidence estimated at 7 to 14 per 1 million in the general population.[@b1-cmo-6-2012-189]--[@b11-cmo-6-2012-189],[@b36-cmo-6-2012-189],[@b37-cmo-6-2012-189] The discovery of the mutation of KIT (CD117) in GIST proto-oncogene was fundamental in order to understand the genesis and classification of these tumors.[@b24-cmo-6-2012-189] The fact that the cells of GISTs show ultrastructural features and cellular markers, typical of Interstitial Cells of Cajal (ICC), has supported the hypothesis that they may originate from these cells.[@b10-cmo-6-2012-189],[@b19-cmo-6-2012-189]--[@b23-cmo-6-2012-189] ICC are characterized by expression of KIT (CD117).[@b22-cmo-6-2012-189] A subset of GISTs has mutation in the KIT-related kinase gene: platelet-derived growth factor receptor alpha (PDGFRA).[@b39-cmo-6-2012-189],[@b40-cmo-6-2012-189] Proto-oncogene KIT mutations are found in more than 95% of GISTs, and in 5%--10% of cases mutations of the PDGFRA gene.[@b4-cmo-6-2012-189],[@b7-cmo-6-2012-189],[@b10-cmo-6-2012-189],[@b16-cmo-6-2012-189],[@b23-cmo-6-2012-189],[@b24-cmo-6-2012-189],[@b38-cmo-6-2012-189] The mutations mainly involving exon 11 of KIT gene are less frequently mutated exons 9, 13, 14 and 17 and exons 12 and 18 of PDGFRA gene.[@b16-cmo-6-2012-189],[@b22-cmo-6-2012-189],[@b26-cmo-6-2012-189] Mutations of KIT lead to a constitutional activation of tyrosine kinase function that determines resistance to cellular proliferation and apoptosis.[@b23-cmo-6-2012-189] KIT and PDGFRA mutations appear to be mutually exclusive oncogenic mechanisms in GISTs.[@b39-cmo-6-2012-189],[@b40-cmo-6-2012-189] It is not clear whether the presence or absence of a mutation in the KIT or PDGFRA genes per se influences prognosis, although delections of the exon 11 have been linked to poor survival.[@b16-cmo-6-2012-189],[@b22-cmo-6-2012-189],[@b26-cmo-6-2012-189],[@b41-cmo-6-2012-189],[@b42-cmo-6-2012-189] Staining for other markers is more variable: BCL 2 80%, CD34 70%, muscle specific actin 50%, smooth muscle actine 35%, S100 10% and desmin 5%.[@b10-cmo-6-2012-189],[@b22-cmo-6-2012-189],[@b26-cmo-6-2012-189] GISTs are usually composed of a population of spindle cells (60%--70%) or epithelioid cells (20%) and the reminder consists of a mixture of these two morphologies.[@b10-cmo-6-2012-189],[@b16-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b22-cmo-6-2012-189],[@b23-cmo-6-2012-189] GISTs have been documented in all parts of the gastrointestinal tract: especially in the stomach (60% to 70%) and small intestine (25% to 35%), with rare occurrence in the colon and rectum (5%), esophagus (\<2%) and appendix, gallbladder and pancreas.[@b10-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b25-cmo-6-2012-189],[@b26-cmo-6-2012-189] Some GISTs, primary in the omentum, mesentery or retroperitoneum, are unrelated to the tubular gastrointestinal tract and they are so-called Extra-gastrointestinal Stromal Tumor (EGISTs).[@b4-cmo-6-2012-189],[@b10-cmo-6-2012-189],[@b12-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b25-cmo-6-2012-189]--[@b31-cmo-6-2012-189],[@b58-cmo-6-2012-189] EGISTs are identical by histological and immunohistochemical features with GISTs.[@b4-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b22-cmo-6-2012-189],[@b23-cmo-6-2012-189],[@b25-cmo-6-2012-189],[@b26-cmo-6-2012-189],[@b32-cmo-6-2012-189],[@b58-cmo-6-2012-189] However, incidence, histogenesis, clinical and prognostic factors of EGISTs are not defined yet.[@b4-cmo-6-2012-189],[@b13-cmo-6-2012-189]--[@b15-cmo-6-2012-189]-,[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189]--[@b32-cmo-6-2012-189],[@b58-cmo-6-2012-189] EGISTs show staining of KIT, marker of Interstitial Cells of Cajal which are normally present just in the gut wall.[@b4-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189],[@b32-cmo-6-2012-189] The reason why this kind of cells, which normally are in the gut wall, can stay in the retroperitoneum, omentum or mesentery and originate a tumor is not clear yet. It can be hypothesized that these tumors originate from common precursor cells which differentiate into the Interstitial Cells of Cajal type outside from the gut wall.[@b10-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189],[@b32-cmo-6-2012-189],[@b43-cmo-6-2012-189],[@b44-cmo-6-2012-189] EGISTs are rare tumors. A total of 99 omental and mesenteric EGISTs are reported in four published series from 1999 to 2008.[@b18-cmo-6-2012-189],[@b44-cmo-6-2012-189]--[@b46-cmo-6-2012-189] EGISTs arising in the retroperitoneum are uncommon. To date, only 58 cases of EGISTs of the retroperitoneum have been reported in Literature[@b4-cmo-6-2012-189],[@b12-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189]--[@b29-cmo-6-2012-189],[@b33-cmo-6-2012-189]--[@b35-cmo-6-2012-189],[@b58-cmo-6-2012-189] ([Table 1](#t1-cmo-6-2012-189){ref-type="table"}). Reith et al[@b18-cmo-6-2012-189] reported 48 cases of EGISTs and 6 of them originated in the retroperitoneum. 17 cases of EGSTs of the retroperitoneum have been reported by Yamamoto et al[@b4-cmo-6-2012-189] and by Barreda Bolanos et al.[@b15-cmo-6-2012-189] These studies were frequently limited by the lack of information available on clinical, pathological and prognostic features.[@b27-cmo-6-2012-189] The absence of specific symptoms associated with an objective, not always measurable, makes difficult an early diagnosis. These tumors grow silently and consequently they are discovered once they have reached a significant size, causing symptoms of compression.[@b7-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b27-cmo-6-2012-189] In the case we reported, there were non-specific symptoms (posterior abdominal pain) and there was no palpable mass on physical examination. The CT-scan and MRI are the standard imaging techniques of these tumors,[@b7-cmo-6-2012-189],[@b12-cmo-6-2012-189],[@b47-cmo-6-2012-189]--[@b51-cmo-6-2012-189] but the preoperative diagnosis based on radiological data is very difficult.[@b12-cmo-6-2012-189],[@b49-cmo-6-2012-189]--[@b51-cmo-6-2012-189] Small tumors usually appear like a well-defined homogeneous mass, large tumors tend to be ill defined and inhomogeneous, sometimes with calcification and necrosis. Malignant forms can be described like large lesions (\>10 cm) with wall invasion or hepatic metastasis.[@b52-cmo-6-2012-189] Radiological findings in EGSTs are often similar to those of other retroperironeal tumors (sarcomas, malignant fibrous histiocytoma, liposarcoma, leiomyosarcoma, fibrosarcoma).[@b12-cmo-6-2012-189],[@b50-cmo-6-2012-189],[@b51-cmo-6-2012-189] In our case the CT scan showed a periaortic mass (diameter 6 × 6 × 8 cm). The retroperitoneal mass was placed in the paravertebral region, level L3--L4, on the left side of the aorta, in front of the left ilio-psoas muscle adherent to it. The lesion showed heterogeneous and persistent enhancement even in scans acquired in the late phase after administration of contrast. No adenopathies or local infiltration were found ([Fig. 1](#f1-cmo-6-2012-189){ref-type="fig"}). Contrary to what was reported by other authors[@b12-cmo-6-2012-189] the CT-scan did not show in our case the presence of peripheral calcifications or central necrosis. The biopsy eco- or CT-guided help to plan the best treatment, and risk of peritoneal dissemination is negligible. [@b7-cmo-6-2012-189] Limitations of pre-operative image-guided FNA may be caused by inadequate sampling of the target mass lesion, as in our case, or by the difficulty in performing a mitotic count on aspiration cytology smears.[@b7-cmo-6-2012-189] The microscopic evaluation in the case we studied showed a neoplastic cellular proliferation composed of spindle cells by type. The immunohistochemical study showed positive for CD117, and focal positivity for S-100 protein and NSE, negative for CD34, smooth muscle and skeletal actin ([Fig. 2](#f2-cmo-6-2012-189){ref-type="fig"}). Surgical removal is the gold standard treatment for non metastatic EGISTs.[@b7-cmo-6-2012-189],[@b11-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b48-cmo-6-2012-189],[@b53-cmo-6-2012-189],[@b54-cmo-6-2012-189] Adjacent organs adherent to the mass should be resected en bloc with the tumor, in order to avoid capsule rupture and intra-abdominal spillage[@b7-cmo-6-2012-189],[@b11-cmo-6-2012-189],[@b15-cmo-6-2012-189],[@b53-cmo-6-2012-189]--[@b55-cmo-6-2012-189] Laparoscopic surgery should be avoided in large tumors because of the high risk of tumor rupture and consequent peritoneal seeding. A laparoscopic resection might be accepted in case of small tumors (\<2--5 cm).[@b55-cmo-6-2012-189],[@b56-cmo-6-2012-189] Prognostic factors in the case of EGISTs are not well encoded in the literature.[@b4-cmo-6-2012-189],[@b13-cmo-6-2012-189]--[@b15-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b27-cmo-6-2012-189]--[@b32-cmo-6-2012-189] The location, size, cellularity, mitotic activity and necrosis are reported to be the most accurate predictors of a poor outcome.[@b4-cmo-6-2012-189],[@b16-cmo-6-2012-189],[@b18-cmo-6-2012-189],[@b30-cmo-6-2012-189],[@b44-cmo-6-2012-189] Omental EGISTs have a better prognosis than those in the mesenteric location.[@b45-cmo-6-2012-189] In respect to GIST size, it is generally accepted as one of the main prognostic factors (low risk cut off \<5 cm in diameter),[@b16-cmo-6-2012-189] although other authors[@b15-cmo-6-2012-189] found no correlation between tumor size and survival. Some authors[@b15-cmo-6-2012-189] have reported a shorter survival in patients younger than 50 years. Ruiz-Tovar et al[@b29-cmo-6-2012-189] revealed in a multivariate analysis that masculine gender, constitutional syndrome, abdominal mass at diagnosis, small bowel and retroperitoneum location and actin- negative tumors are bad prognostic factors. High cellularity, mitotic activity (\>2 mitoses/50 HPF) and the presence of necrosis are significantly associated with an adverse outcome.[@b18-cmo-6-2012-189] For Barreda- Bolanos et al[@b15-cmo-6-2012-189] the low mitotic index associated with metastases did not reflect a good prognosis of disease. On the basis of a combination of the mitotic rate and MIB-1 labeling index, three risk categories can be identified: the high-risk group (≥5/50 HPF with ≥10% Ki-67); the intermediate-risk group (≥5/50 HPF with \<10% Ki-67, or, \<5/50 HPF with ≥10% Ki-67), and the low-risk group (\<5/50 HPF with \<10% Ki-67).[@b4-cmo-6-2012-189] The exon 11 mutation causes a more aggressive biological behavior.[@b16-cmo-6-2012-189],[@b22-cmo-6-2012-189],[@b26-cmo-6-2012-189] In our case, morphological and immunohistochemical features of tumor leaded to a diagnosis of EGIST as an intermediate risk form according to the risk assessment proposed by Fletcher et al[@b16-cmo-6-2012-189] and a low risk form according to risk assessment proposed by Yamamoto et al.[@b4-cmo-6-2012-189] The introduction of drugs that inhibit tyrosine kinase activity of receptors (imatinib mesylate) has resulted in a significant increase in survival from 18 to 60 months in patients with mesenchymal tumors with mutations of the KIT gene in advanced stage.[@b57-cmo-6-2012-189]

At present, there is no consensus in the literature about the use of imatinib mesylate as standard treatment for patients with localized cancer KIT.[@b11-cmo-6-2012-189],[@b13-cmo-6-2012-189] A randomized study showed that administration of these drugs for a period of one year prolongs relapse free-survival in localized tumors with KIT, completely removed, with diameter \>3 cm, when compared with placebo.[@b59-cmo-6-2012-189] The use of imatinib mesylate is recommended for ≥1 year in patients with KIT resectable at high risk of recurrence.[@b59-cmo-6-2012-189] Li et al[@b13-cmo-6-2012-189] have also shown that adjuvant imatinib can improve 1-, 2- and 3-years relapse-free survival rates in patients at intermediate or high risk of recurrence after complete tumor resection.

Not all authors who describe the EGISTs of the retroperitoneum reported the use of imatinib mesylate after surgery ([Table 1](#t1-cmo-6-2012-189){ref-type="table"}). Our patient underwent a R0 section and the tumor was classified as an intermediate and low-risk according to the classification of Fletcher et al[@b16-cmo-6-2012-189] and Yamamoto et al[@b4-cmo-6-2012-189] respectively, and therefore there was no need to proceed with the use of imatinib mesylate. The mean follow-up of patients reported in several case studies often do not exceed 24 months and this could lead to bias. Our patient is alive and disease free at 24 months after surgery.

In summary, CD117 positive stromal tumors, although extremely rare, can involve retroperitoneum. This should be considered when imaging studies reveal an abdominal tumor involving the retroperitoneum without a connection to the gastrointestinal tract. In most cases a preoperative diagnosis is not possible. Complete surgical removal of the mass and, when possible, "en bloc" with contiguous tissues and regional lymph nodes, is the gold standard therapy for non metastatic EGISTs. There is no consensus about the use of inhibitors of receptors of tyrosine kinase activity in these tumors. More studies are necessary to evaluate the role of molecular biology in targeted therapy. It is difficult to assess their malignant potential and their overall prognosis although some Authors[@b4-cmo-6-2012-189],[@b16-cmo-6-2012-189] reported criteria that appear to be useful in predicting the risk of recurrence.

As a result of the rarity of reports of primary EGISTs of retroperitoneum we need to analyze the data of reported cases in the literature in order to gain a better understanding about the pathogenesis, clinicopathological features, prognosis and optimal treatment of this disease.
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![Axial CT-scan shows a retroperitoneal mass (60 × 60 × 80 mm), solid, placed in left paravertebral region, level L3--L4, on the left side of aorta, ilio-psoas muscle adherent.](cmo-6-2012-189f1){#f1-cmo-6-2012-189}

![Immunohistochemically, the tumor cells test strongly positive for c-kit (×200).](cmo-6-2012-189f2){#f2-cmo-6-2012-189}
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Case review of the primary EGIST of the retroperitoneum.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                                        Age/Gender   Size (cm)           Pattern   Cellularity       Mitoses no./50 HPF   Ki-67 LI   c-kit mutation   Imatinib                       Outcome
  ---------------------------------------------- ------------ ------------------- --------- ----------------- -------------------- ---------- ---------------- ------------------------------ --------------
  Reith et al[@b18-cmo-6-2012-189]               44/M         32                  S         Low               1                    NA         NA               NA                             NED/11 mo

                                                 41/F         26                  E         Low               0                    NA         NA               NA                             NED/37 mo

                                                 45/F         16.5                E         High              49                   NA         NA               NA                             DOD/5 mo

                                                 67/F         9                   E         Low               2                    NA         NA               NA                             NED/40 mo

                                                 45/F         18                  E         Low               2                    NA         NA               NA                             NED/67 mo

                                                 82/F         12.5                S         Low               1                    NA         NA               NA                             NED/24 mo

  Takao et al[@b12-cmo-6-2012-189]               70/F         16 × 15 × 18        S         Low               NA                   NA         NA               NA                             NED/12 mo

  Park et al[@b58-cmo-6-2012-189]                32/M         13.3 × 10.2 × 9.4   S         High              6--10                NA         NA               Yes                            NED/6 mo

  Ferchichi et al[@b34-cmo-6-2012-189]           54/M         10                  S         NA                6                    NA         NA               NA                             NA

  Takizawa et al[@b35-cmo-6-2012-189]            67/M         3.7 × 5.5           S         NA                10--15               3--5       NA               NA                             NED/18 mo

  Yamamoto et al[@b4-cmo-6-2012-189]             80/F         15                  S         Moderate          9                    3.9        NA               NA                             NED/9 mo

                                                 46/F         7                   E         High              1                    2.3        Exon 11          NA                             NED/86 mo

                                                 69/M         18                  S         High              12                   17.2       NA               NA                             DOD/37 mo

                                                 68/F         15                  S         High              5                    32         ND               NA                             DOD/136 mo

                                                 45/F         10                  S         High              19                   10         NA               NA                             DOD/50 mo

                                                 63/M         6                   S         Moderate          4                    4.1        Exon 11          NA                             DOD/96 mo

                                                 45/M         3                   E         Moderate          1                    2          Exon 11          NA                             NED/86 mo

                                                 50/F         14                  S         High              10                   1          NA               NA                             DOD/68 mo

                                                 30/F         14                  E         Low               9                    1.8        Exon 11          NA                             DOD/21 mo

                                                 67/F         10                  S         Moderate          20                   33.9       Exon 11          NA                             AWD/6 mo

                                                 56/F         12                  S         High              20                   12.1       ND               NA                             DOD/48 mo

                                                 48/F         11                  S         High              50                   1          Exon 11          NA                             DOD/28 mo

                                                 52/F         10                  S         High              25                   11.5       NA               NA                             DOD/60 mo

                                                 54/M         35                  S         High              0                    2          NA               NA                             NED/94 mo

                                                 57/F         9                   S         Moderate          5                    4.2        ND               NA                             DOD/9 mo

                                                 74/F         14                  S         Moderate          4                    1.9        ND               NA                             DOD/24 mo

                                                 75/F         8                   S         Moderate          10                   2.7        ND               NA                             NA

  Goh BKP et al[@b27-cmo-6-2012-189]             57/F         22                  S         High              \>10                 NA         NA               NA                             AWD/42 mo

  Fuertes J et al[@b33-cmo-6-2012-189]           41/M         13                  Mixed     Moderate          6                    40         NA               Yes                            NED/24 mo

  Vij M et al[@b28-cmo-6-2012-189]               9 cases      NA                  NA        NA                NA                   NA         NA               NA                             NA

  Ruiz-Tovar J et al[@b29-cmo-6-2012-189]        3 cases      NA                  NA        NA                NA                   NA         NA               1 patient received treatment   AWD/12 mo

  Barreda Bolanos F et al[@b15-cmo-6-2012-189]   17 cases     \>10 (16 cases)     NA        High (2 cases)\   NA                   NA         NA               2 cases                        1 AWD/29 mo\
                                                                                            Low (3 cases)                                                                                     1 AWD/60 mo

  Present case 2011                              39/M         7.5                 S         Low               5                    5          7                NO                             NED/24 mo
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** S, spindle; E, epitheliod; NA, not available; NED, no evidence disease; mo, month; AWD, alive with disease; DOD, dead of disease; ND, not done; LI, labeling index.
